SIRT2-IN-9 |
| Catalog No.GC66026 |
SIRT2-IN-9 (compound 12) is a selective inhibitor of SRIT2 with an IC50 value of 1.3 μM. SIRT2-IN-9 inhibits proliferative activity of MCF-7 breast cancer cells. SIRT2-IN-9 can be used for the research of cancer.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 522650-91-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SIRT2-IN-9 (compound 12) is a selective inhibitor of SRIT2 with an IC50 value of 1.3 μM. SIRT2-IN-9 inhibits proliferative activity of MCF-7 breast cancer cells. SIRT2-IN-9 can be used for the research of cancer[1].
SIRT2-IN-9 (1-100 μM; 15 min) dose-dependently inhibits SRIT2 with an IC50 value of 1.3 μM, and inhibits SRIT1 and SRIT3 with IC50s ??300 μM[1].
SIRT2-IN-9 (0-50 μM; 72 h) affects cell viability of MCF-7 cells[1].
SIRT2-IN-9 (0-50 μM; 6 h) affects acetylation of α-tubulin protein[1].
Cell Proliferation Assay[1]
| Cell Line: | MCF-7 breast cancer cell line |
| Concentration: | 0-50 μM |
| Incubation Time: | 72 hours |
| Result: | Dose-dependently inhibited cell proliferation of MCF-7 breast cancer cells. |
Western Blot Analysis[1]
| Cell Line: | MCF-7 breast cancer cell line |
| Concentration: | 6.25, 12.5, 25 and 50 μM |
| Incubation Time: | 6 hours |
| Result: | Dose-dependently increased acetylation of α-tubulin protein. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *